FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094906106> ?p ?o ?g. }

• W3094906106 endingPage "540" @default.
• W3094906106 startingPage "527" @default.
• W3094906106 abstract "BUP-XR (a.k.a. RBP-6000 or SUBLOCADE™) is an extended-release subcutaneous buprenorphine formulation for the treatment of opioid use disorder. BUP-XR was designed to provide sustained buprenorphine exposure throughout the monthly dosing interval, at concentrations sufficient to control all aspects of the disease (withdrawal, craving, and blockade of opioid subjective effects).To characterize the population pharmacokinetics of BUP-XR based on phase II and phase III data and to evaluate whether target therapeutic concentrations were reached with the dosing regimens evaluated in the phase III program.The population pharmacokinetic analysis included 570 subjects with opioid use disorder who received up to 12 monthly BUP-XR injections following induction with sublingual buprenorphine.In phase III studies, target therapeutic concentrations of buprenorphine were achieved from the first injection and maintained over the entire treatment duration. Buprenorphine plasma concentration-time profiles were well described by a two-compartment model, with first-order absorption for sublingual buprenorphine and a dual absorption submodel for BUP-XR. A covariate analysis evaluated the effects of subjects' demographic characteristics, laboratory data, and genetic status regarding buprenorphine-metabolizing enzymes. Only two covariates, body mass index and body weight, were retained in the final model. Overall, their effects were not of sufficient magnitude to justify a dose adjustment. Finally, pharmacokinetic simulations showed that buprenorphine plasma concentrations decreased slowly after discontinuation of treatment and that a 2-week occasional delay in dosing would not impact efficacy, which translated into labeling claims.In conclusion, the present analysis led to the development of a robust population pharmacokinetic model and confirms the ability of BUP-XR to deliver and maintain therapeutic plasma concentrations over the entire treatment duration." @default.
• W3094906106 created "2020-11-09" @default.
• W3094906106 creator A5030198338 @default.
• W3094906106 creator A5040023070 @default.
• W3094906106 creator A5046687750 @default.
• W3094906106 creator A5050047645 @default.
• W3094906106 creator A5071929032 @default.
• W3094906106 date "2020-11-02" @default.
• W3094906106 modified "2023-10-07" @default.
• W3094906106 title "Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials" @default.
• W3094906106 cites W1971962043 @default.
• W3094906106 cites W1972479462 @default.
• W3094906106 cites W1990071324 @default.
• W3094906106 cites W1998236008 @default.
• W3094906106 cites W2000740780 @default.
• W3094906106 cites W2020365240 @default.
• W3094906106 cites W2040327352 @default.
• W3094906106 cites W2043122373 @default.
• W3094906106 cites W2052036680 @default.
• W3094906106 cites W2056888894 @default.
• W3094906106 cites W2058734479 @default.
• W3094906106 cites W2069246292 @default.
• W3094906106 cites W2098976686 @default.
• W3094906106 cites W2099536555 @default.
• W3094906106 cites W2157070455 @default.
• W3094906106 cites W2163956523 @default.
• W3094906106 cites W2283026346 @default.
• W3094906106 cites W2413133000 @default.
• W3094906106 cites W2805664586 @default.
• W3094906106 cites W2885019613 @default.
• W3094906106 cites W2916034192 @default.
• W3094906106 cites W2922501327 @default.
• W3094906106 cites W3015322623 @default.
• W3094906106 cites W4247665917 @default.
• W3094906106 doi "https://doi.org/10.1007/s40262-020-00957-0" @default.
• W3094906106 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8016750" @default.
• W3094906106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33135125" @default.
• W3094906106 hasPublicationYear "2020" @default.
• W3094906106 type Work @default.
• W3094906106 sameAs 3094906106 @default.
• W3094906106 citedByCount "14" @default.
• W3094906106 countsByYear W30949061062021 @default.
• W3094906106 countsByYear W30949061062022 @default.
• W3094906106 countsByYear W30949061062023 @default.
• W3094906106 crossrefType "journal-article" @default.
• W3094906106 hasAuthorship W3094906106A5030198338 @default.
• W3094906106 hasAuthorship W3094906106A5040023070 @default.
• W3094906106 hasAuthorship W3094906106A5046687750 @default.
• W3094906106 hasAuthorship W3094906106A5050047645 @default.
• W3094906106 hasAuthorship W3094906106A5071929032 @default.
• W3094906106 hasBestOaLocation W30949061061 @default.
• W3094906106 hasConcept C112705442 @default.
• W3094906106 hasConcept C126322002 @default.
• W3094906106 hasConcept C170493617 @default.
• W3094906106 hasConcept C2776029756 @default.
• W3094906106 hasConcept C2776239304 @default.
• W3094906106 hasConcept C2776316548 @default.
• W3094906106 hasConcept C2777288759 @default.
• W3094906106 hasConcept C2777972943 @default.
• W3094906106 hasConcept C2778715236 @default.
• W3094906106 hasConcept C2778949969 @default.
• W3094906106 hasConcept C2779418921 @default.
• W3094906106 hasConcept C2781063702 @default.
• W3094906106 hasConcept C2908647359 @default.
• W3094906106 hasConcept C42219234 @default.
• W3094906106 hasConcept C71924100 @default.
• W3094906106 hasConcept C98274493 @default.
• W3094906106 hasConcept C99454951 @default.
• W3094906106 hasConceptScore W3094906106C112705442 @default.
• W3094906106 hasConceptScore W3094906106C126322002 @default.
• W3094906106 hasConceptScore W3094906106C170493617 @default.
• W3094906106 hasConceptScore W3094906106C2776029756 @default.
• W3094906106 hasConceptScore W3094906106C2776239304 @default.
• W3094906106 hasConceptScore W3094906106C2776316548 @default.
• W3094906106 hasConceptScore W3094906106C2777288759 @default.
• W3094906106 hasConceptScore W3094906106C2777972943 @default.
• W3094906106 hasConceptScore W3094906106C2778715236 @default.
• W3094906106 hasConceptScore W3094906106C2778949969 @default.
• W3094906106 hasConceptScore W3094906106C2779418921 @default.
• W3094906106 hasConceptScore W3094906106C2781063702 @default.
• W3094906106 hasConceptScore W3094906106C2908647359 @default.
• W3094906106 hasConceptScore W3094906106C42219234 @default.
• W3094906106 hasConceptScore W3094906106C71924100 @default.
• W3094906106 hasConceptScore W3094906106C98274493 @default.
• W3094906106 hasConceptScore W3094906106C99454951 @default.
• W3094906106 hasIssue "4" @default.
• W3094906106 hasLocation W30949061061 @default.
• W3094906106 hasLocation W30949061062 @default.
• W3094906106 hasLocation W30949061063 @default.
• W3094906106 hasOpenAccess W3094906106 @default.
• W3094906106 hasPrimaryLocation W30949061061 @default.
• W3094906106 hasRelatedWork W2056888894 @default.
• W3094906106 hasRelatedWork W2113427158 @default.
• W3094906106 hasRelatedWork W2120531170 @default.
• W3094906106 hasRelatedWork W2912405124 @default.
• W3094906106 hasRelatedWork W2948529948 @default.
• W3094906106 hasRelatedWork W3010234073 @default.
• W3094906106 hasRelatedWork W3094906106 @default.

• next